Movement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed

Market Focus

Jun 12

On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.

On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.

This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.

Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1169123803"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1169123803\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1169123803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 01:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1169123803","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed","media":"Market Focus","content":"<p><p>On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.</p><p>On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.</p><p>This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.</p><p>Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 01:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.</p><p>On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.</p><p>This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.</p><p>Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1169123803","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1169123803","pubTimestamp":1781200084,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.On the news front, the company disclosed preliminary clinical results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"动静快讯|Arrowhead Pharmaceuticals常规交易涨5.89%阿尔茨海默病siRNA药物初步临床数据披露","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"On June 11, Arrowhead Pharmaceuticals rose 5.89% in regular trading, trading at $74.995/share, with turnover of $45.59 million.On the news front, the company disclosed preliminary clinical results for ARO-MAPT7, an siRNA drug developed on its TRiM BBB (blood-brain barrier) platform. The drug utilizes siRNA conjugated with a transferrin receptor-targeting ligand, administered via subcutaneous injection, designed to efficiently cross the blood-brain barrier and silence the MAPT gene throughout the brain for the treatment of Alzheimer's disease and other Tau protein disorders.This data release marks a key milestone for the company in central nervous system RNA interference therapeutics. The market responded positively to the demonstrated potential of Arrowhead's BBB delivery technology platform, which addresses one of the most significant challenges in neurological drug development — delivering therapeutic agents across the blood-brain barrier.Within the Biotechnology sector, Amgen gained 5.17%, Gilead Sciences rose 4.67%, AbbVie advanced 0.68%, and Nuvalent added 0.1%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}